Company profile: Epitomics
1.1 - Company Overview
Company description
- Provider of monoclonal antibody technology and life science research tools, developing proprietary RabMAb® (Rabbit Monoclonal Antibody) antibodies with superior binding affinity, specificity, and bioactivity for research and diagnostic applications. Offerings include primary and secondary antibodies, recombinant options, antibody panels, proteins, and kits and reagents including ELISA kits.
Products and services
- Antibodies: In vivo-grade antibodies validated for commercial use, offered for research and diagnostic applications, including a chimera with a mouse IgG2c backbone for specific in vivo use
- Kits and Reagents: Assay-grade kits and reagents essential for life science research, including ELISA kits and other assay tools for experimental detection and quantification workflows
- Primary Antibodies: Research-grade primary antibodies leveraging proprietary RabMAb rabbit monoclonal technology deliver superior binding affinity, specificity, and bioactivity to detect and quantify antigens, including monoclonal, polyclonal, and recombinant monoclonal options
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Epitomics
Culture Biosciences
HQ: United States
Website
- Description: Provider of cloud-connected bioreactors and Console software enabling remote, real-time design, monitoring, and analysis of cell culture and bioprocess experiments, plus bioprocess development services including clone screening, process characterization, media screening, and process optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Culture Biosciences company profile →
Emulate
HQ: United States
Website
- Description: Provider of advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emulate company profile →
Taconic Biosciences
HQ: United States
Website
- Description: Provider of animal models and related laboratory services for biomedical research, offering over 4,500 genetically engineered mouse and rat models, including repository models, standard strains, GEMs, and humanized immune system models. Services include custom model generation, colony management, FcResolv NOG-EXL superimmunodeficient mice, and the Wild Mouse Microbiome toolkit for drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taconic Biosciences company profile →
Atera Labs
HQ: Luxembourg
Website
- Description: Provider of advanced human tissue models and tissue engineering solutions, specializing in R&D, validation, manufacturing and commercialization to deliver reliable, cost-effective, high-quality test methods for product evaluation, gradually reducing and replacing animal experimentation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atera Labs company profile →
Q Chip
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical drug delivery, developing a range of sustained-release biogeneric and biotherapies products (Q-Sphera).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q Chip company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Epitomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Epitomics
2.2 - Growth funds investing in similar companies to Epitomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Epitomics
4.2 - Public trading comparable groups for Epitomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →